SEC Form 4 · accession 0002083206-26-000009
Lexeo Therapeutics, Inc. · LXEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Louis Edward Tamayo
Officer — Chief Financial Officer
Period of report
Sep 24, 2026
Accepted (ET)
Sep 28, 2026 · 5:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001907108
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.39 | Sep 24, 2026 | A | 54,750 | A | — | Sep 23, 2036 | Common Stock | 54,750 | 54,750 | D |
Explanation of responses
- F125% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.